PL404315A1 - Lek i kompozycja farmaceutyczna zawierajaca 5-hydroksy-7-chloro-1[2-metylo-4(2-metylobenzoiloamino)benzoilo]-2,3,4,5-tetrahydro-1H-benzoazepine do leczenia ciezkiej niewydolnosci serca oraz zastosowanie tego zwiazku do wytwarzania leku - Google Patents
Lek i kompozycja farmaceutyczna zawierajaca 5-hydroksy-7-chloro-1[2-metylo-4(2-metylobenzoiloamino)benzoilo]-2,3,4,5-tetrahydro-1H-benzoazepine do leczenia ciezkiej niewydolnosci serca oraz zastosowanie tego zwiazku do wytwarzania lekuInfo
- Publication number
- PL404315A1 PL404315A1 PL404315A PL40431504A PL404315A1 PL 404315 A1 PL404315 A1 PL 404315A1 PL 404315 A PL404315 A PL 404315A PL 40431504 A PL40431504 A PL 40431504A PL 404315 A1 PL404315 A1 PL 404315A1
- Authority
- PL
- Poland
- Prior art keywords
- drug
- heart failure
- methylbenzoylamino
- tetrahydro
- benzoyl
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 5
- 206010019280 Heart failures Diseases 0.000 title abstract 4
- 229940079593 drug Drugs 0.000 title abstract 4
- GYHCTFXIZSNGJT-UHFFFAOYSA-N tolvaptan Chemical compound CC1=CC=CC=C1C(=O)NC(C=C1C)=CC=C1C(=O)N1C2=CC=C(Cl)C=C2C(O)CCC1 GYHCTFXIZSNGJT-UHFFFAOYSA-N 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 2
- 206010002383 Angina Pectoris Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000037081 physical activity Effects 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Przedmiotem wynalazku jest lek oraz kompozycja farmaceutyczna do leczenia ciezkiej niewydolnosci serca klasy IV wedlug Nowojorskiego Towarzystwa Kardiologicznego, w przypadku której pacjenci sa niezdolni do podjecia jakiejkolwiek aktywnosci fizycznej bez odczuwania dolegliwosci, objawy niewydolnosci serca lub dusznicy bolesnej sa obecne nawet w spoczynku, a podjecie jakiejkolwiek aktywnosci fizycznej nasila dolegliwosci, przy czym lek oraz kompozycja zawieraja jako skladnik czynny 5-hydroksy-7-chloro-1-[2-metylo-4-(2-metylobenzoiloamino) benzoilo]-2,3,4,5-tetrahydro-1H-benzoazepine lub jej farmaceutycznie dopuszczalna sól. Przedmiotem wynalazku jest równiez zastosowanie 5-hydroksy-7-chloro-1-[2-metylo-4-(2-metylobenzoiloamino) benzoilo]-2,3,4,5-tetrahydro-1H-benzoazepiny lub jej farmaceutycznie dopuszczalnej soli do wytwarzania leku odpowiedniego do leczenia ciezkiej niewydolnosci serca klasy IV wedlug Nowojorskiego Towarzystwa Kardiologicznego.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44887803P | 2003-02-24 | 2003-02-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL404315A1 true PL404315A1 (pl) | 2013-08-05 |
Family
ID=32908667
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL404315A PL404315A1 (pl) | 2003-02-24 | 2004-02-23 | Lek i kompozycja farmaceutyczna zawierajaca 5-hydroksy-7-chloro-1[2-metylo-4(2-metylobenzoiloamino)benzoilo]-2,3,4,5-tetrahydro-1H-benzoazepine do leczenia ciezkiej niewydolnosci serca oraz zastosowanie tego zwiazku do wytwarzania leku |
| PL373432A PL218069B1 (pl) | 2003-02-24 | 2004-02-23 | Lek i kompozycja farmaceutyczna do zastosowania w leczeniu ciężkiej niewydolności serca oraz zastosowanie 5-hydroksy-7-chloro-1-[ 2-metylo-4-( 2-metylobenzoiloamino) benzoilo]-2,3,4,5-tetrahydro-1H-benzoazepiny do wytwarzania leku do leczenia ciężkiej niewydolności serca |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL373432A PL218069B1 (pl) | 2003-02-24 | 2004-02-23 | Lek i kompozycja farmaceutyczna do zastosowania w leczeniu ciężkiej niewydolności serca oraz zastosowanie 5-hydroksy-7-chloro-1-[ 2-metylo-4-( 2-metylobenzoiloamino) benzoilo]-2,3,4,5-tetrahydro-1H-benzoazepiny do wytwarzania leku do leczenia ciężkiej niewydolności serca |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US7423032B2 (pl) |
| EP (2) | EP2000142A1 (pl) |
| JP (2) | JP4771937B2 (pl) |
| KR (1) | KR100706727B1 (pl) |
| CN (1) | CN100577171C (pl) |
| AR (1) | AR043259A1 (pl) |
| AT (1) | ATE411803T1 (pl) |
| AU (2) | AU2004212842B9 (pl) |
| BR (1) | BRPI0405657A (pl) |
| CA (1) | CA2493475A1 (pl) |
| CY (1) | CY1108583T1 (pl) |
| DE (1) | DE602004017283D1 (pl) |
| DK (1) | DK1596868T3 (pl) |
| ES (1) | ES2315640T3 (pl) |
| MX (1) | MXPA05001623A (pl) |
| MY (1) | MY143740A (pl) |
| NO (1) | NO335369B1 (pl) |
| PL (2) | PL404315A1 (pl) |
| PT (1) | PT1596868E (pl) |
| RU (2) | RU2346689C2 (pl) |
| SI (1) | SI1596868T1 (pl) |
| TW (1) | TWI322689B (pl) |
| WO (1) | WO2004073716A1 (pl) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7468390B2 (en) * | 2002-01-17 | 2008-12-23 | Novartis Ag | Methods of treatment and pharmaceutical composition |
| TWI322689B (en) * | 2003-02-24 | 2010-04-01 | Otsuka Pharma Co Ltd | Method for treating severe heart failure and medicament therefor |
| DE102005003632A1 (de) | 2005-01-20 | 2006-08-17 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Katheter für die transvaskuläre Implantation von Herzklappenprothesen |
| US20070213813A1 (en) | 2005-12-22 | 2007-09-13 | Symetis Sa | Stent-valves for valve replacement and associated methods and systems for surgery |
| US20100004206A1 (en) | 2005-12-27 | 2010-01-07 | Makoto Komatsu | Water-soluble benzoazepine compound and its pharmaceutical composition |
| JP5076327B2 (ja) * | 2006-02-01 | 2012-11-21 | 味の素株式会社 | 分岐鎖アミノ酸の心不全適応 |
| US7896915B2 (en) | 2007-04-13 | 2011-03-01 | Jenavalve Technology, Inc. | Medical device for treating a heart valve insufficiency |
| CN103550233A (zh) * | 2007-05-15 | 2014-02-05 | 大塚制药株式会社 | 使用血管加压素拮抗剂与蒽环类化疗试剂以减少心脏中毒和/或提高存活率的方法 |
| TWI405574B (zh) * | 2007-06-21 | 2013-08-21 | Otsuka Pharma Co Ltd | 藥學固體製劑及其製造方法 |
| BR112012021347A2 (pt) | 2008-02-26 | 2019-09-24 | Jenavalve Tecnology Inc | stent para posicionamento e ancoragem de uma prótese valvular em um local de implantação no coração de um paciente |
| US9044318B2 (en) | 2008-02-26 | 2015-06-02 | Jenavalve Technology Gmbh | Stent for the positioning and anchoring of a valvular prosthesis |
| US10856978B2 (en) | 2010-05-20 | 2020-12-08 | Jenavalve Technology, Inc. | Catheter system |
| JP2013526388A (ja) | 2010-05-25 | 2013-06-24 | イエナバルブ テクノロジー インク | 人工心臓弁、及び人工心臓弁とステントを備える経カテーテル搬送体内プロテーゼ |
| JP5477413B2 (ja) * | 2012-04-24 | 2014-04-23 | 味の素株式会社 | 分岐鎖アミノ酸の心不全適応 |
| EP4098226A1 (en) | 2013-08-30 | 2022-12-07 | JenaValve Technology, Inc. | Endoprosthesis comprising a radially collapsible frame and a prosthetic valve |
| WO2016150806A1 (en) | 2015-03-20 | 2016-09-29 | Jenavalve Technology, Inc. | Heart valve prosthesis delivery system and method for delivery of heart valve prosthesis with introducer sheath |
| JP6767388B2 (ja) | 2015-05-01 | 2020-10-14 | イェーナヴァルヴ テクノロジー インコーポレイテッド | 心臓弁置換におけるペースメーカー割合を低減させるデバイス及び方法 |
| EP4183371A1 (en) | 2016-05-13 | 2023-05-24 | JenaValve Technology, Inc. | Heart valve prosthesis delivery system and method for delivery of heart valve prosthesis with introducer sheath and loading system |
| CN110392557A (zh) | 2017-01-27 | 2019-10-29 | 耶拿阀门科技股份有限公司 | 心脏瓣膜模拟 |
| CN110174474B (zh) * | 2019-05-24 | 2022-02-18 | 石家庄四药有限公司 | 复方电解质注射液(ⅱ)中l-苹果酸异构体的检测方法 |
| CN112121051B (zh) * | 2020-09-30 | 2021-06-18 | 郑州大学 | 莫扎伐坦在制备抗消化道肿瘤药物中的应用 |
| US12171658B2 (en) | 2022-11-09 | 2024-12-24 | Jenavalve Technology, Inc. | Catheter system for sequential deployment of an expandable implant |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01102124A (ja) | 1987-10-14 | 1989-04-19 | Kubota Ltd | コンクリート構造体支持構造 |
| US5753677A (en) * | 1989-10-20 | 1998-05-19 | Otsuka Pharmaceutical Co., Ltd. | Benzoheterocyclic compounds |
| US5258510A (en) * | 1989-10-20 | 1993-11-02 | Otsuka Pharma Co Ltd | Benzoheterocyclic compounds |
| KR0167349B1 (ko) | 1989-10-20 | 1999-02-18 | 오스카 아끼히꼬 | 벤조헤테로 고리 화합물 |
| TW249201B (pl) | 1992-07-02 | 1995-06-11 | Otsuka Pharma Co Ltd | |
| JPH0680641A (ja) | 1992-09-01 | 1994-03-22 | Otsuka Pharmaceut Co Ltd | 光学活性な５−ヒドロキシベンゾアゼピン誘導体の製造法 |
| TW354762B (en) * | 1993-02-23 | 1999-03-21 | Otsuka Pharma Co Ltd | Agent for prophylaxis or treatment of cataract |
| JP2694319B2 (ja) | 1993-12-24 | 1997-12-24 | 大塚製薬株式会社 | 抗潰瘍剤 |
| JP3002766B2 (ja) * | 1994-12-09 | 2000-01-24 | 大塚製薬株式会社 | 脳浮腫治療剤 |
| JPH10120592A (ja) | 1996-10-22 | 1998-05-12 | Otsuka Pharmaceut Co Ltd | メニエール病乃至メニエール症候群治療剤 |
| JP4210355B2 (ja) * | 1997-07-03 | 2009-01-14 | 大塚製薬株式会社 | 固形製剤組成物 |
| US20030103983A1 (en) * | 2002-05-09 | 2003-06-05 | Pressler Milton Lethan | Ace inhibitor-vasopressin antagonist combinations |
| MXPA02006352A (es) | 2000-01-26 | 2002-11-29 | Warner Lambert Co | Combinaciones del inhibidor ace con el antagonista vasopresina. |
| US20030008860A1 (en) * | 2002-05-09 | 2003-01-09 | Bakker-Arkema Rebecca Guggemos | Treatment of congestive heart failure |
| ATE367815T1 (de) * | 2000-10-04 | 2007-08-15 | Astellas Pharma Inc | Verwendung von einem vasopressin-antagonisten wie conivaptan zur herstellung eines medikaments für die behandlung der pulmonalen hypertension |
| TWI322689B (en) * | 2003-02-24 | 2010-04-01 | Otsuka Pharma Co Ltd | Method for treating severe heart failure and medicament therefor |
-
2004
- 2004-02-05 TW TW093102582A patent/TWI322689B/zh not_active IP Right Cessation
- 2004-02-17 MY MYPI20040510A patent/MY143740A/en unknown
- 2004-02-23 CN CN200480000735A patent/CN100577171C/zh not_active Expired - Lifetime
- 2004-02-23 BR BR0405657-4A patent/BRPI0405657A/pt not_active Application Discontinuation
- 2004-02-23 PL PL404315A patent/PL404315A1/pl unknown
- 2004-02-23 SI SI200430894T patent/SI1596868T1/sl unknown
- 2004-02-23 AT AT04713672T patent/ATE411803T1/de active
- 2004-02-23 WO PCT/JP2004/002085 patent/WO2004073716A1/en not_active Ceased
- 2004-02-23 DK DK04713672T patent/DK1596868T3/da active
- 2004-02-23 ES ES04713672T patent/ES2315640T3/es not_active Expired - Lifetime
- 2004-02-23 AR ARP040100557A patent/AR043259A1/es unknown
- 2004-02-23 MX MXPA05001623A patent/MXPA05001623A/es active IP Right Grant
- 2004-02-23 AU AU2004212842A patent/AU2004212842B9/en not_active Expired
- 2004-02-23 PL PL373432A patent/PL218069B1/pl unknown
- 2004-02-23 DE DE602004017283T patent/DE602004017283D1/de not_active Expired - Lifetime
- 2004-02-23 EP EP08162362A patent/EP2000142A1/en not_active Withdrawn
- 2004-02-23 CA CA002493475A patent/CA2493475A1/en not_active Abandoned
- 2004-02-23 PT PT04713672T patent/PT1596868E/pt unknown
- 2004-02-23 EP EP04713672A patent/EP1596868B1/en not_active Expired - Lifetime
- 2004-02-23 RU RU2005102110/14A patent/RU2346689C2/ru active
- 2004-02-23 JP JP2006502681A patent/JP4771937B2/ja not_active Expired - Lifetime
- 2004-02-23 KR KR1020057002579A patent/KR100706727B1/ko not_active Expired - Lifetime
- 2004-02-23 US US10/523,020 patent/US7423032B2/en not_active Expired - Lifetime
-
2005
- 2005-02-02 NO NO20050569A patent/NO335369B1/no unknown
-
2008
- 2008-05-05 US US12/149,578 patent/US7749993B2/en not_active Expired - Lifetime
- 2008-08-15 RU RU2008133654/14A patent/RU2008133654A/ru not_active Application Discontinuation
- 2008-11-20 CY CY20081101341T patent/CY1108583T1/el unknown
-
2009
- 2009-03-19 AU AU2009201109A patent/AU2009201109A1/en not_active Abandoned
-
2011
- 2011-03-07 JP JP2011049403A patent/JP2011148806A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL404315A1 (pl) | Lek i kompozycja farmaceutyczna zawierajaca 5-hydroksy-7-chloro-1[2-metylo-4(2-metylobenzoiloamino)benzoilo]-2,3,4,5-tetrahydro-1H-benzoazepine do leczenia ciezkiej niewydolnosci serca oraz zastosowanie tego zwiazku do wytwarzania leku | |
| Madhusoodanan et al. | Clinical experience with quetiapine in elderly patients with psychotic disorders | |
| WO2005065069A3 (en) | Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease | |
| KR20200016889A (ko) | 과다 졸림증을 치료하기 위한 방법 및 조성물 | |
| EA200800056A1 (ru) | Каннабиноидный активный фармацевтический ингредиент для лекарственных форм | |
| ATE493981T1 (de) | Einmal tägliche dosierformen von trospium | |
| WO2002088100A3 (de) | Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel | |
| BR9915610A (pt) | Preparações farmacêuticas combinadas | |
| CA2474430A1 (en) | A combination of a thrombolytic agent and levosimendan for the treatment of acute myocardial infarction | |
| MXPA02006511A (es) | Complejo que comprende factor inhibidor de osteoclastogenesis y polisacarido. | |
| CA2450915A1 (en) | Use of levosimendan and beta-adrenergic receptor antagonist for the treatment of heart failure | |
| JP2002535367A5 (pl) | ||
| CA2501772A1 (en) | Use of dihydroimidazolones for the treatment of epilepsy in dogs | |
| RU2008110933A (ru) | Применение амброксола для лечения риновирусных инфекций | |
| HUP0301408A2 (hu) | Szulodexid alkalmazása diabetikus vesebetegség kezelésére szolgáló orális gyógyszerkészítmény előállítására | |
| AR030551A1 (es) | Uso de nefiracetam para la fabricacion de un medicamento para eltratamiento de la neurodegeneracion y composicion farmaceutica resultante | |
| AU2012276476B2 (en) | Pharmaceutical composition for treating premature ejaculation and method for treating premature ejaculation | |
| MA28036A1 (fr) | Utilisation d'oxcarbazepine dans le traitement de la douleur liee a la neuropathie diabetique et dans l'amelioration du sommeil | |
| CA2469702A1 (en) | Darifenacin for use in the treatment of urgency induced by overactive bladder | |
| Jašović-Gašić et al. | P. 6.024 Antidepressants versus clozapine in the treatment of depressive syndrome in schizophrenia | |
| PT1490049E (pt) | Citalopram para o tratamento da pre3ssao sanguinia elevada. | |
| TW200515912A (en) | Use of oxcarbazepine for the treatment of diabetic neuropathic pain and the improvement of sleep | |
| HUP0401587A2 (hu) | Új elnyújtott kibocsátású orális adagolási forma | |
| Hemmeter et al. | P. 6.023 Effect of zopiclone on cognition and sleep-EEG in healthy elderly volunteers | |
| Kamiński et al. | P. 6.025 Amiodipine enhances the protective activity of ethosuximide and valproate magnesium against pentylenetetrazol-induced seizures in mice |